Literature DB >> 25171700

The Tahoe Study: bias in the interpretation of Papanicolaou test results when human papillomavirus status is known.

Ann T Moriarty1, Ritu Nayar, Terry Arnold, Lisa Gearries, Andrew Renshaw, Nicole Thomas, Rhona Souers.   

Abstract

CONTEXT: Knowledge of human papillomavirus (HPV) status is expected to bias the morphologic evaluation of Papanicolaou (Pap) test results.
OBJECTIVE: To characterize Pap test result interpretive bias when the HPV status is known at the microscopic evaluation.
DESIGN: Forty HPV-positive liquid-based Pap test results initially interpreted as negative for squamous intraepithelial lesion or malignancy were selected from a quality assurance program, separated into 2 groups of 20 slides each, and circulated in 2 groups to 22 members of the College of American Pathologists Cytopathology Committee. Each member reviewed each case and indicated whether the result was negative for squamous intraepithelial lesion or malignancy or was an epithelial cell abnormality (ECA). The participants assessed the severity of ECAs using the Bethesda System. The participants were not informed of the HPV status in the initial review round. Each group of 20 slides was then distributed to the opposite group (to avoid slide recall), and the participants were informed that all slides were from patients who were high-risk HPV positive. Differences in the responses between groups were analyzed by χ(2) test and Cochran-Mantel-Haenszel test at the .05 significance level.
RESULTS: Without knowledge of the HPV status, slides were more often categorized as negative for squamous intraepithelial lesion or malignancy and less likely identified as an ECA (P < .001). There was an increase across all categories of ECAs in the biased responses compared with the unbiased responses (P = .002).
CONCLUSIONS: Knowledge of positive HPV status biases morphologic Pap test result interpretation. If the HPV status is positive, observers are more likely to report a Pap test result as abnormal across all categories of ECAs.

Entities:  

Mesh:

Year:  2014        PMID: 25171700     DOI: 10.5858/arpa.2012-0115-CP

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

1.  p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population.

Authors:  Roosmarijn Luttmer; Maaike G Dijkstra; Peter J F Snijders; Johannes Berkhof; Folkert J van Kemenade; Lawrence Rozendaal; Theo J M Helmerhorst; René H M Verheijen; W Abraham Ter Harmsel; W Marchien van Baal; Peppino G C M Graziosi; Wim G V Quint; Johan W M Spruijt; Dorenda K E van Dijken; Daniëlle A M Heideman; Chris J L M Meijer
Journal:  Mod Pathol       Date:  2016-05-06       Impact factor: 7.842

2.  Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.

Authors:  Renée Mf Ebisch; Judith van der Horst; Meyke Hermsen; L Lucia Rijstenberg; Judith Em Vedder; Johan Bulten; Remko P Bosgraaf; Viola Mj Verhoef; Daniëlle Am Heideman; Peter Jf Snijders; Chris Jlm Meijer; Folkert J van Kemenade; Leon Fag Massuger; Willem Jg Melchers; Ruud Lm Bekkers; Albert G Siebers
Journal:  Mod Pathol       Date:  2017-03-17       Impact factor: 7.842

3.  FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women.

Authors:  Roosmarijn Luttmer; Lise M A De Strooper; Maaike G Dijkstra; Johannes Berkhof; Peter J F Snijders; Renske D M Steenbergen; Folkert J van Kemenade; Lawrence Rozendaal; Theo J M Helmerhorst; René H M Verheijen; W Abraham Ter Harmsel; W Marchien van Baal; Peppino G C M Graziosi; Wim G V Quint; Johan W M Spruijt; Dorenda K E van Dijken; Daniëlle A M Heideman; Chris J L M Meijer
Journal:  Br J Cancer       Date:  2016-07-14       Impact factor: 7.640

4.  Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.

Authors:  Lise M A De Strooper; Johannes Berkhof; Renske D M Steenbergen; Birgit I Lissenberg-Witte; Peter J F Snijders; Chris J L M Meijer; Daniëlle A M Heideman
Journal:  Int J Cancer       Date:  2018-04-27       Impact factor: 7.396

5.  Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol.

Authors:  Maribel Almonte; Raúl Murillo; Gloria Inés Sánchez; Paula González; Annabelle Ferrera; María Alejandra Picconi; Carolina Wiesner; Aurelio Cruz-Valdez; Eduardo Lazcano-Ponce; Jose Jerónimo; Catterina Ferreccio; Elena Kasamatsu; Laura Mendoza; Guillermo Rodríguez; Alejandro Calderón; Gino Venegas; Verónica Villagra; Silvio Tatti; Laura Fleider; Carolina Terán; Armando Baena; María de la Luz Hernández; Mary Luz Rol; Eric Lucas; Sylvaine Barbier; Arianis Tatiana Ramírez; Silvina Arrossi; María Isabel Rodríguez; Emmanuel González; Marcela Celis; Sandra Martínez; Yuly Salgado; Marina Ortega; Andrea Verónica Beracochea; Natalia Pérez; Margarita Rodríguez de la Peña; María Ramón; Pilar Hernández-Nevarez; Margarita Arboleda-Naranjo; Yessy Cabrera; Brenda Salgado; Laura García; Marco Antonio Retana; María Celeste Colucci; Javier Arias-Stella; Yenny Bellido-Fuentes; María Liz Bobadilla; Gladys Olmedo; Ivone Brito-García; Armando Méndez-Herrera; Lucía Cardinal; Betsy Flores; Jhacquelin Peñaranda; Josefina Martínez-Better; Ana Soilán; Jacqueline Figueroa; Benedicta Caserta; Carlos Sosa; Adrián Moreno; Juan Mural; Franco Doimi; Diana Giménez; Hernando Rodríguez; Oscar Lora; Silvana Luciani; Nathalie Broutet; Teresa Darragh; Rolando Herrero
Journal:  BMJ Open       Date:  2020-05-24       Impact factor: 2.692

6.  The impact of knowledge of HPV positivity on cytology triage in primary high-risk HPV screening.

Authors:  Clare A Aitken; Kim M Holtzer-Goor; Anne Uyterlinde; Adriaan Jc van den Brule; Hans C van der Linden; Cornelis J Huijsmans; Inge McM de Kok; Folkert J van Kemenade
Journal:  J Med Screen       Date:  2019-07-25       Impact factor: 2.136

7.  Cytology interpretation after a change to HPV testing in primary cervical screening: Observational study from the English pilot.

Authors:  Matejka Rebolj; Christopher S Mathews; Karin Denton
Journal:  Cancer Cytopathol       Date:  2022-04-04       Impact factor: 4.264

8.  Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates.

Authors:  Kirsten Rozemeijer; Corine Penning; Albert G Siebers; Steffie K Naber; Suzette M Matthijsse; Marjolein van Ballegooijen; Folkert J van Kemenade; Inge M C M de Kok
Journal:  Cancer Causes Control       Date:  2015-10-12       Impact factor: 2.506

9.  HPV Infection Significantly Accelerates Glycogen Metabolism in Cervical Cells with Large Nuclei: Raman Microscopic Study with Subcellular Resolution.

Authors:  Katarzyna Sitarz; Krzysztof Czamara; Joanna Bialecka; Malgorzata Klimek; Barbara Zawilinska; Slawa Szostek; Agnieszka Kaczor
Journal:  Int J Mol Sci       Date:  2020-04-11       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.